Skip to main content
Top
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort

Authors: Jason H Karnes, Taimour Y Langaee, Caitrin W McDonough, Shin-Wen Chang, Miguel Ramos, James R Catlin Jr, Octavio E Casanova, Yan Gong, Carl J Pepine, Julie A Johnson, Rhonda M Cooper-DeHoff

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Recently, the high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American populations. We sought to investigate the HMGA1-diabetes association and to characterize IVS5-13insC allele frequencies and linkage disequilibrium (LD) in 3,070 Caucasian, Hispanic, and African American patients from the INternational VErapamil SR-Trandolapril STudy (INVEST).

Methods

INVEST was a randomized, multicenter trial comparing two antihypertensive treatment strategies in an ethnically diverse cohort of hypertensive, coronary artery disease patients. Controls, who were diabetes-free throughout the study, and type 2 diabetes cases, either prevalent or incident, were genotyped for IVS5-13insC using Taqman®, confirmed with Pyrosequencing and Sanger sequencing. For LD analysis, genotyping for eight additional HMGA1 single nucleotide polymorphisms (SNPs) was performed using the Illumina® HumanCVD BeadChip. We used logistic regression to test association of the HMGA1 IVS5-13insC and diabetes, adjusted for age, gender, body mass index, and percentage European, African, and Native American ancestry.

Results

We observed IVS5-13insC minor allele frequencies consistent with previous literature in Caucasians and African Americans (0.03 in cases and 0.04 in controls for both race/ethnic groups), and higher frequencies in Hispanics (0.07 in cases and 0.07 in controls). The IVS5-13insC was not associated with type 2 diabetes overall (odds ratio 0.98 [0.76-1.26], p=0.88) or in any race/ethnic group. Pairwise LD (r2) of IVS5-13insC and rs9394200, a SNP previously used as a tag SNP for IVS5-13insC, was low (r2=0.47 in Caucasians, r2=0.25 in Hispanics, and r2=0.06 in African Americans). Furthermore, in silico analysis suggested a lack of functional consequences for the IVS5-13insC variant.

Conclusions

Our results suggest that IVS5-13insC is not a functional variant and not associated with type 2 diabetes in an ethnically diverse, hypertensive, coronary artery disease population. Larger, more adequately powered studies need to be performed to confirm our findings.

Trial registration

clinicaltrials.gov (NCT00133692)
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010, 87: 293-301. 10.1016/j.diabres.2010.01.026.CrossRefPubMed Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010, 87: 293-301. 10.1016/j.diabres.2010.01.026.CrossRefPubMed
2.
go back to reference Herder C, Roden M: Genetics of type 2 diabetes: pathophysiologic and clinical relevance. Eur J Clin Invest. 2011, 41: 679-692. 10.1111/j.1365-2362.2010.02454.x.CrossRefPubMed Herder C, Roden M: Genetics of type 2 diabetes: pathophysiologic and clinical relevance. Eur J Clin Invest. 2011, 41: 679-692. 10.1111/j.1365-2362.2010.02454.x.CrossRefPubMed
3.
go back to reference Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010, 42: 579-589. 10.1038/ng.609.PubMedCentralCrossRefPubMed Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010, 42: 579-589. 10.1038/ng.609.PubMedCentralCrossRefPubMed
4.
go back to reference Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimaki M, Humphries SE: Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010, 340: b4838-10.1136/bmj.b4838.PubMedCentralCrossRefPubMed Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimaki M, Humphries SE: Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010, 340: b4838-10.1136/bmj.b4838.PubMedCentralCrossRefPubMed
5.
go back to reference Chiefari E, Tanyolac S, Paonessa F, Pullinger CR, Capula C, Iiritano S, Mazza T, Forlin M, Fusco A, Durlach V: Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA. 2011, 305: 903-912. 10.1001/jama.2011.207.CrossRefPubMed Chiefari E, Tanyolac S, Paonessa F, Pullinger CR, Capula C, Iiritano S, Mazza T, Forlin M, Fusco A, Durlach V: Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA. 2011, 305: 903-912. 10.1001/jama.2011.207.CrossRefPubMed
6.
go back to reference Liu L, Ding H, Wang HR, Xu YJ, Cui GL, Wang PH, Yuan G, Yu XF, Wang DW: Polymorphism of HMGA1 is associated with increased risk of type 2 diabetes among Chinese individuals. Diabetologia. 2012, 55: 1685-1688. 10.1007/s00125-012-2518-0.CrossRefPubMed Liu L, Ding H, Wang HR, Xu YJ, Cui GL, Wang PH, Yuan G, Yu XF, Wang DW: Polymorphism of HMGA1 is associated with increased risk of type 2 diabetes among Chinese individuals. Diabetologia. 2012, 55: 1685-1688. 10.1007/s00125-012-2518-0.CrossRefPubMed
7.
go back to reference Marquez M, Huyvaert M, Perry JR, Pearson RD, Falchi M, Morris AP, Vivequin S, Lobbens S, Yengo L, Gaget S: Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes. 2012, 61: 524-530. 10.2337/db11-0728.PubMedCentralCrossRefPubMed Marquez M, Huyvaert M, Perry JR, Pearson RD, Falchi M, Morris AP, Vivequin S, Lobbens S, Yengo L, Gaget S: Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes. 2012, 61: 524-530. 10.2337/db11-0728.PubMedCentralCrossRefPubMed
8.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS: Executive Summary: Heart Disease and Stroke Statistics–2012 Update: A Report From the American Heart Association. Circulation. 2012, 125: 188-197.CrossRefPubMed Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS: Executive Summary: Heart Disease and Stroke Statistics–2012 Update: A Report From the American Heart Association. Circulation. 2012, 125: 188-197.CrossRefPubMed
9.
go back to reference Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P: Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998, 32: 1228-1237. 10.1016/S0735-1097(98)00423-9.CrossRefPubMed Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P: Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998, 32: 1228-1237. 10.1016/S0735-1097(98)00423-9.CrossRefPubMed
10.
go back to reference Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003, 290: 2805-2816. 10.1001/jama.290.21.2805.CrossRefPubMed Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003, 290: 2805-2816. 10.1001/jama.290.21.2805.CrossRefPubMed
11.
go back to reference Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006, 98: 890-894. 10.1016/j.amjcard.2006.04.030.CrossRefPubMed Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006, 98: 890-894. 10.1016/j.amjcard.2006.04.030.CrossRefPubMed
12.
go back to reference Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ: INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther. 2009, 7: 1329-1340. 10.1586/erc.09.102.PubMedCentralCrossRefPubMed Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ: INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther. 2009, 7: 1329-1340. 10.1586/erc.09.102.PubMedCentralCrossRefPubMed
13.
go back to reference Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN: Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One. 2008, 3: e3583-10.1371/journal.pone.0003583.PubMedCentralCrossRefPubMed Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN: Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One. 2008, 3: e3583-10.1371/journal.pone.0003583.PubMedCentralCrossRefPubMed
14.
go back to reference Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81: 559-575. 10.1086/519795.PubMedCentralCrossRefPubMed Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81: 559-575. 10.1086/519795.PubMedCentralCrossRefPubMed
15.
go back to reference Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics. 2000, 155: 945-959.PubMedCentralPubMed Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics. 2000, 155: 945-959.PubMedCentralPubMed
16.
go back to reference Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ: Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients–findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006, 151: 1072-1079. 10.1016/j.ahj.2005.05.024.CrossRefPubMed Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ: Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients–findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006, 151: 1072-1079. 10.1016/j.ahj.2005.05.024.CrossRefPubMed
17.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.CrossRefPubMed
18.
go back to reference Chelala C, Khan A, Lemoine NR: SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics. 2009, 25: 655-661. 10.1093/bioinformatics/btn653.PubMedCentralCrossRefPubMed Chelala C, Khan A, Lemoine NR: SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics. 2009, 25: 655-661. 10.1093/bioinformatics/btn653.PubMedCentralCrossRefPubMed
19.
go back to reference Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003, 31: 3568-3571. 10.1093/nar/gkg616.PubMedCentralCrossRefPubMed Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003, 31: 3568-3571. 10.1093/nar/gkg616.PubMedCentralCrossRefPubMed
20.
go back to reference Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007, 447: 661-678. 10.1038/nature05911.CrossRef Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007, 447: 661-678. 10.1038/nature05911.CrossRef
21.
go back to reference Froguel P, Marquez M, Cauchi S: Response to comment on: Marquez et al. Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes 2012;61:524–530. Diabetes. 2012, 61: e15-10.2337/db12-0800.PubMedCentralCrossRefPubMed Froguel P, Marquez M, Cauchi S: Response to comment on: Marquez et al. Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes 2012;61:524–530. Diabetes. 2012, 61: e15-10.2337/db12-0800.PubMedCentralCrossRefPubMed
22.
go back to reference Goldman N, Lin IF, Weinstein M, Lin YH: Evaluating the quality of self-reports of hypertension and diabetes. J Clin Epidemiol. 2003, 56: 148-154. 10.1016/S0895-4356(02)00580-2.CrossRefPubMed Goldman N, Lin IF, Weinstein M, Lin YH: Evaluating the quality of self-reports of hypertension and diabetes. J Clin Epidemiol. 2003, 56: 148-154. 10.1016/S0895-4356(02)00580-2.CrossRefPubMed
23.
go back to reference Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004, 110: 1572-1578. 10.1161/01.CIR.0000142047.28024.F2.CrossRefPubMed Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004, 110: 1572-1578. 10.1161/01.CIR.0000142047.28024.F2.CrossRefPubMed
24.
go back to reference Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005, 112: 1339-1346.CrossRefPubMed Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005, 112: 1339-1346.CrossRefPubMed
25.
go back to reference Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA. 2001, 286: 1882-1885. 10.1001/jama.286.15.1882.CrossRefPubMed Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA. 2001, 286: 1882-1885. 10.1001/jama.286.15.1882.CrossRefPubMed
26.
go back to reference Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012, 90: 410-425. 10.1016/j.ajhg.2011.12.022.PubMedCentralCrossRefPubMed Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012, 90: 410-425. 10.1016/j.ajhg.2011.12.022.PubMedCentralCrossRefPubMed
Metadata
Title
Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort
Authors
Jason H Karnes
Taimour Y Langaee
Caitrin W McDonough
Shin-Wen Chang
Miguel Ramos
James R Catlin Jr
Octavio E Casanova
Yan Gong
Carl J Pepine
Julie A Johnson
Rhonda M Cooper-DeHoff
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-12

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.